We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-4.76%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$86.2M
AUM Growth
-$13.2M
Cap. Flow
-$1.05M
Cap. Flow %
-1.22%
Top 10 Hldgs %
64.54%
Holding
46
New
7
Increased
19
Reduced
6
Closed
12

Top Buys

Rank Stock Value
1
WHWK
Whitehawk Therapeutics
WHWK
+$4.08M
2
SLNO
Soleno Therapeutics
SLNO
+$3.27M
3
OCS icon
Oculis Holding
OCS
+$2.56M
4
MRK icon
Merck
MRK
+$2.15M
5
SRZN icon
Surrozen
SRZN
+$1.98M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$6.28M
2
PCVX icon
Vaxcyte
PCVX
+$3.68M
3
RVMD icon
Revolution Medicines
RVMD
+$1.83M
4
MRSN
Mersana Therapeutics
MRSN
+$1.6M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$1.53M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
1
Ocular Therapeutix
OCUL
$1.84B
$8.94M 10.37%
1,219,724
+108,653
+10% +$835K
INSM icon
2
Insmed
INSM
$21.3B
$8.09M 9.38%
106,074
+1,274
+1% +$97.5K
TRML
3
DELISTED
Tourmaline Bio
TRML
$6.49M 7.53%
426,882
+75,040
+21% +$1.2M
WHWK
4
Whitehawk Therapeutics
WHWK
$196M
$6.07M 7.04%
3,410,402
+1,561,000
+84% +$4.08M
ELVN icon
5
Enliven Therapeutics
ELVN
$4.15B
$5.22M 6.05%
265,269
-2,099
-0.8% -$45.2K
TRVI icon
6
Trevi Therapeutics
TRVI
$2.54B
$4.94M 5.73%
785,961
+14,003
+2% +$66.8K
SLNO
7
DELISTED
Soleno Therapeutics
SLNO
$4.8M 5.56%
+67,136
New +$3.27M
ARGX icon
8
argenx
ARGX
$52B
$4.16M 4.82%
7,023
+113
+2% +$71.3K
ASND icon
9
Ascendis Pharma A/S
ASND
$16B
$3.64M 4.22%
23,340
+364
+2% +$52K
PRAX icon
10
Praxis Precision Medicines
PRAX
$8.52B
$3.3M 3.83%
87,141
+19,641
+29% +$1.23M
CDTX
11
DELISTED
Cidara Therapeutics
CDTX
$2.71M 3.14%
125,708
+71,235
+131% +$1.58M
OCS icon
12
Oculis Holding
OCS
$718M
$2.38M 2.76%
+125,000
New +$2.56M
RVMD icon
13
Revolution Medicines
RVMD
$38.8B
$2.36M 2.73%
66,662
-45,038
-40% -$1.83M
LQDA icon
14
Liquidia Corp
LQDA
$7.46B
$2.26M 2.63%
153,482
+15,773
+11% +$230K
DRUG
15
Bright Minds Biosciences
DRUG
$724M
$2.16M 2.5%
59,748
-9,376
-14% -$343K
BBOT
16
BridgeBio Oncology
BBOT
$661M
$2.12M 2.45%
187,257
+6,312
+3% +$67.8K
MRK icon
17
Merck
MRK
$316B
$2.06M 2.39%
+22,994
New +$2.15M
SRZN icon
18
Surrozen
SRZN
$253M
$1.98M 2.3%
+170,000
New +$1.98M
EWTX icon
19
Edgewise Therapeutics
EWTX
$4.13B
$1.88M 2.18%
85,454
-2,204
-3% -$57.8K
MREO
20
Mereo BioPharma
MREO
$50.4M
$1.78M 2.07%
791,815
+12,507
+2% +$35.4K
UNCY icon
21
Unicycive Therapeutics
UNCY
$138M
$1.35M 1.57%
235,289
+4,989
+2% +$30.4K
JAZZ icon
22
Jazz Pharmaceuticals
JAZZ
$15.8B
$1.19M 1.38%
+9,575
New +$1.25M
VSTM icon
23
Verastem
VSTM
$500M
$1.06M 1.23%
+176,000
New +$1.08M
GILD icon
24
Gilead Sciences
GILD
$163B
$1.04M 1.21%
9,298
+148
+2% +$15.3K
TERN
25
DELISTED
Terns Pharmaceuticals
TERN
$899K 1.04%
325,550
-121,950
-27% -$498K
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Acuta Capital Partners held 46 positions worth $86.2M, down 13% from $99.4M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Acuta Capital Partners's Q1 2025 filing shows 7 new, 19 increased, 6 reduced and 12 closed positions. Its largest new stake was Soleno Therapeutics: 67,136 shares worth $4.8M. The largest sale was Crinetics Pharmaceuticals, an estimated $6.28M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Acuta Capital Partners's largest Q1 2025 buy was Soleno Therapeutics: 67,136 shares worth $4.8M.
  • Acuta Capital Partners added most to Whitehawk Therapeutics in Q1 2025, an estimated $4.08M increase.
  • Acuta Capital Partners's biggest Q1 2025 reduction was Revolution Medicines, cutting an estimated $1.83M.
  • Acuta Capital Partners fully exited Crinetics Pharmaceuticals in Q1 2025, selling an estimated $6.28M.
  • Acuta Capital Partners's ten largest holdings make up 65% of its $86.2M portfolio in Q1 2025.
  • Acuta Capital Partners opened 7 new positions and closed 12 in Q1 2025.
  • Acuta Capital Partners's portfolio value fell 13% quarter-over-quarter to $86.2M.

Based on Acuta Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.